Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oric Pharmaceuticals (ORIC) Accumulated Expenses (2019 - 2026)

Oric Pharmaceuticals filings provide 8 years of Accumulated Expenses readings, the most recent being $3.8 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 5.07% to $3.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $3.8 million through Mar 2026, down 5.07% year-over-year, with the annual reading at $8.1 million for FY2025, 65.26% down from the prior year.
  • Accumulated Expenses hit $3.8 million in Q1 2026 for Oric Pharmaceuticals, down from $8.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $23.3 million in Q4 2024 and bottomed at $2.2 million in Q1 2022.
  • Average Accumulated Expenses over 5 years is $9.3 million, with a median of $6.9 million recorded in 2025.
  • The largest annual shift saw Accumulated Expenses crashed 69.5% in 2022 before it soared 310.24% in 2023.
  • Oric Pharmaceuticals' Accumulated Expenses stood at $5.3 million in 2022, then soared by 266.94% to $19.5 million in 2023, then grew by 19.39% to $23.3 million in 2024, then plummeted by 65.26% to $8.1 million in 2025, then plummeted by 53.0% to $3.8 million in 2026.
  • Per Business Quant, the three most recent readings for ORIC's Accumulated Expenses are $3.8 million (Q1 2026), $8.1 million (Q4 2025), and $6.9 million (Q3 2025).